Prelude Therapeutics (PRLD) Short-term Investments (2021 - 2026)

Prelude Therapeutics (PRLD) has 6 years of Short-term Investments data on file, last reported at $59.8 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 1.69% year-over-year to $59.8 million; the trailing twelve-month figure through Mar 2026 stood at $59.8 million (up 1.69% YoY), and the FY2025 full-year result was $68.0 million, down 43.9% from the prior year.
• Short-term Investments fell to $59.8 million in Q1 2026, from $68.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $228.5 million in Q2 2023 to a low of $7.4 million in Q3 2025.
• A 5-year average of $140.7 million and a median of $154.1 million in 2023 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments grew 24.76% in 2023 and sank 94.79% in 2025, its largest moves.
• Tracing PRLD's Short-term Investments over 5 years: stood at $171.1 million in 2022, then grew by 21.34% to $207.6 million in 2023, then tumbled by 41.66% to $121.1 million in 2024, then sank by 43.9% to $68.0 million in 2025, then retreated by 12.01% to $59.8 million in 2026.
• Business Quant data shows PRLD's Short-term Investments at $59.8 million in Q1 2026, $68.0 million in Q4 2025, and $7.4 million in Q3 2025.